Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Suspended 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Lymphoid 1

Conditions

Recurrence 1Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 1Lymphoma, T-Cell 1Lymphoma, Large-Cell, Anaplastic 1Lymphoma, Large B-Cell, Diffuse 1Lymphoma 1Leukemia-Lymphoma, Adult T-Cell 1Immunoblastic Lymphadenopathy 1Epstein-Barr Virus Infections 1

Interventions

Specimen Handling 8venetoclax 7Azacitidine 6Cyclophosphamide 4fludarabine phosphate 3Tacrolimus 3Etoposide 3Biopsy 3Vincristine 2Mitoxantrone 2Melphalan 2Cytarabine 2vactosertib 1regorafenib 1prednylidene 1ponatinib 1methyl cis-3,4-diamino-2,3,4,6-tetradeoxy-alpha-L-lyxo-hexopyranoside Pt(II) 1iadademstat 1gilteritinib 1fludarabine 1deltacortene 1decitabine and cedazuridine drug combination 1cyclo-tetrakis(bis(1-phenyl-3-methyl-4-benzoylpyrazolon-5-ato)mu-oxotitanium(IV)) 1brincidofovir 1beta-apocarotenoid-14',13'-dioxygenase 1azathiopurine 1ammonium trichloro(dioxoethylene-O,O'-)tellurate 1aldesleukin 1TAK-243 1Stem Cell Transplantation 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Suspended × brincidofovir × Other hematologic neoplasm × Clear all
NCT06761677 2026-02-05

A Phase 1b/2 Study of Intravenous Brincidofovir in Patients With Relapsed or Refractory Lymphoma and Relapsed or Refractory Extranodal Natural Killer/T-cell Lymphoma

SymBio Pharmaceuticals

Phase 1/2 Suspended
43 enrolled
LymphoidOther hematologic neoplasm

Immunoblastic Lymphadenopathy, Lymphoma, Recurrence, Leukemia-Lymphoma, Adult T-Cell, Lymphoma, T-Cell, Lymphoma, Large B-Cell, Diffuse, Lymphoma, Large-Cell, Anaplastic, Epstein-Barr Virus Infections, Precursor T-Cell Lymphoblastic Leukemia-Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡